Shares of Psychemedics Co. (NASDAQ:PMD – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.34 and traded as high as $2.35. Psychemedics shares last traded at $2.35, with a volume of 18,107 shares traded.
Psychemedics Stock Performance
The company’s fifty day simple moving average is $2.32 and its 200 day simple moving average is $2.34. The firm has a market capitalization of $13.79 million, a P/E ratio of -3.00 and a beta of 0.65.
Psychemedics (NASDAQ:PMD – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.14) earnings per share for the quarter. Psychemedics had a negative net margin of 21.50% and a negative return on equity of 68.43%. The firm had revenue of $4.73 million for the quarter.
Psychemedics Company Profile
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.
Recommended Stories
- Five stocks we like better than Psychemedics
- Investing in the High PE Growth Stocks
- California Resources Stock Could Be a Huge Long-Term Winner
- How to Use the MarketBeat Excel Dividend Calculator
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- How to Evaluate a Stock Before BuyingÂ
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.